Home / Going-concern warnings / Scribe Therapeutics, Inc.
Filed 2026-09-02 路 Form 10-Q 路 Accession 0001193125-26-380191 small
Price before filing: $29 (2026-09-01 close, split/dividend-adjusted)
Market cap at flag: $500.0M (2026-09-02) 路 Latest: $324.9M (2026-10-16)
| Window | SCTX | SPY | vs SPY | |
|---|---|---|---|---|
| 30 days | -42.1% | +1.3% | -43.4% | 2026-10-02 |
| 90 days | pending | pending | until 2026-12-01 | |
| 180 days | pending | pending | until 2027-03-01 | |
| 1 year | pending | pending | until 2027-09-02 |
Return from the last close before the filing date to the first close on/after the window end. Pending windows have not fully elapsed. Past performance says nothing certain about the future.
90 days before the flag: 6 insiders bought $71.3M (9 purchases)
30 days after: none reported.
| Date | Insider | Type | Shares | Price | Value | 10b5-1 plan | Source |
|---|---|---|---|---|---|---|---|
| 2026-07-23 | Lucas Svetlana Chief Business Officer | Purchase | 3,000 | $15.00 | $45K | no | Form 4 |
| 2026-07-23 | Parrot David Chief Financial Officer | Purchase | 1,333 | $15.00 | $20K | no | Form 4 |
| 2026-07-23 | Parrot David Chief Financial Officer | Purchase | 1,333 | $15.00 | $20K | no | Form 4 |
| 2026-07-24 | Aghazadeh Behzad (+2 joint filers) Director, 10% owner | Purchase | 2,333,333 | $15.00 | $35.0M | no | Form 4 |
| 2026-07-24 | Aghazadeh Behzad (+2 joint filers) Director, 10% owner | Purchase | 50,000 | $22.31 | $1.1M | no | Form 4 |
| 2026-07-27 | AH Bio Fund II, L.P. (+5 joint filers) 10% owner | Purchase | 333,333 | $15.00 | $5.0M | no | Form 4 |
| 2026-07-27 | GORDON CARL L Director | Purchase | 1,000,000 | $15.00 | $15.0M | no | Form 4 |
| 2026-07-27 | ORBIMED ADVISORS LLC (+1 joint filer) Director | Purchase | 1,000,000 | $15.00 | $15.0M | no | Form 4 |
| 2026-07-28 | Aghazadeh Behzad (+2 joint filers) Director, 10% owner | Purchase | 7,905 | $18.25 | $144K | no | Form 4 |
| 2026-09-02: red flag filed | |||||||
Open-market purchases and sales (Form 4 codes P and S) by officers, directors and 10% owners, by transaction date, from 2026-06-04 to 2026-10-02. Excludes option exercises, grants, gifts and tax withholding. Amended filings replace the originals; joint filings count once. Foreign private issuers do not file Form 4. Many insider sales are pre-scheduled (10b5-1 plans) and are not by themselves a sign of wrongdoing.
"Accordingly, management concluded that the substantial doubt about the Company's ability to continue as a going concern that existed as of June 30, 2026 was alleviated prior to the issuance of these financial statements as a result of the completion of the IPO and concurrent private placement. 2."
Quoted from the filing. Source
Going-concern doubt disclosed, then alleviated: the company said conditions raised substantial doubt about its ability to continue as a going concern, but that its plans or new funding resolve that doubt for the next 12 months. A weaker warning than an unresolved going-concern doubt, but the company recently needed a rescue plan or fresh money to stay afloat.
Source: management disclosure in Form 10-Q (period 2026-06-30)
Status: doubt alleviated (the company says its plans or new funding resolve the substantial doubt it disclosed)
Why this score: substantial doubt disclosed, then alleviated by management's plans or new funding; quarterly (unaudited) disclosure
Read the original filing on SEC.gov →
🔔 Get email alerts for this company
Not investment advice. Automated summary; verify against the filing.
The week's most serious auditor changes, restatements, late filings and going-concern warnings, in plain English. Free. Unsubscribe anytime.
Subscribe to the newsletter →
The signup form didn't load here (often an ad or privacy blocker). This opens beehiiv's secure signup page.
Form not showing? Subscribe on beehiiv →
Newsletter delivered by beehiiv. See our privacy policy.